Related Experiment Video
Updated: Jul 15, 2026
Development of an Insert Co-culture System of Two Cellular Types in the Absence of Cell-Cell Contact
Published on: July 17, 2016
YC-1 attenuates LPS-induced proinflammatory responses and activation of nuclear factor-kappaB in microglia
1College of Medicine, Pharmacological Institute, National Taiwan University, Taipei, Taiwan.
Background And Purpose:
An inflammatory response in the central nervous system mediated by the activation of microglia is a key event in the early stages of the development of neurodegenerative diseases. LPS has been reported to cause marked microglia activation. It is very important to develop drugs that can inhibit microglia activation and neuroinflammation. Here, we investigated the inhibitory effect of YC-1, a known activator of soluble guanylyl cyclase, against LPS-induced inflammatory responses in microglia.
Experimental Approach:
To understand the inhibitory effects of YC-1 on LPS-induced neuroinflammation, primary cultures of rat microglia and the microglia cell line BV-2 were used. To examine the mechanism of action of YC-1, LPS-induced nitric oxide (NO) and prostaglandin E2 (PGE2) production, iNOS, COX-2 and cytokine expression were analyzed by Griess reaction, ELISA, Western blotting and RT-PCR, respectively. The effect of YC-1 on LPS-induced activation of nuclear factor kappa B (NF-kappaB) was studied by NF-kappaB reporter assay and immunofluorocytochemistry.
Key Results:
YC-1 inhibited LPS-induced production of NO and PGE2 in a concentration-dependent manner. The protein and mRNA expression of iNOS and COX-2 in response to LPS application were also decreased by YC-1. In addition, YC-1 effectively reduced LPS-induced expression of the mRNA for the proinflammatory cytokines, TNF-alpha and IL-1beta. Furthermore, YC-1 inhibited LPS-induced NF-kappaB activation in microglia.
Conclusions And Implications:
YC-1 was able to inhibit LPS-induced iNOS and COX-2 expression and NF-kappaB activation, indicating that YC-1 may be developed as an anti-inflammatory neuroprotective agent.
Insights
YC-1 inhibits lipopolysaccharide (LPS)-induced neuroinflammation by reducing nitric oxide, prostaglandin E2, and pro-inflammatory cytokine production. This compound also suppresses nuclear factor kappa B (NF-kappaB) activation, suggesting potential as an anti-inflammatory neuroprotective agent.
Area of Science:
- Neuroscience
- Immunology
- Pharmacology
Background:
- Neuroinflammation, driven by microglia activation, is crucial in neurodegenerative diseases.
- Lipopolysaccharide (LPS) is known to induce significant microglia activation.
- Developing drugs to inhibit microglia activation and neuroinflammation is essential.
Purpose of the Study:
- To investigate the inhibitory effects of YC-1 on LPS-induced inflammatory responses in microglia.
- To explore the mechanism of YC-1's action against neuroinflammation.
Main Methods:
- Primary rat microglia and BV-2 cell line were used to study YC-1's effects.
- Nitric oxide (NO) and prostaglandin E2 (PGE2) production were measured.
- Expression of iNOS, COX-2, TNF-alpha, IL-1beta, and NF-kappaB activation were analyzed.
Main Results:
- YC-1 dose-dependently inhibited LPS-induced NO and PGE2 production.
- YC-1 reduced the expression of iNOS and COX-2 at both mRNA and protein levels.
- YC-1 suppressed LPS-induced mRNA expression of TNF-alpha and IL-1beta, and inhibited NF-kappaB activation.
Conclusions:
- YC-1 effectively inhibits LPS-induced iNOS and COX-2 expression and NF-kappaB activation.
- YC-1 demonstrates potential as a neuroprotective agent with anti-inflammatory properties.
Related Concept Videos
02:26NF-κB-dependent Signaling Pathway
NF-κB-dependent Signaling Mechanism
The heterodimer of NF-κB...
01:24T Cell Types and Functions
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
02:26NF-kB-dependent Signaling Pathway
NF-κB-dependent Signaling Mechanism
The heterodimer of NF-κB...